



Financial Results (Consolidated) for the Nine months ended December 31, 2020

FUJIFILM Holdings Corporation

Kenji Sukeno

President and Chief Operating Officer

Projected date of Quarterly report: February 12, 2021

Projected date of the beginning of cash dividends: —

Reference materials regarding operating results of the current quarter to be prepared: Yes

Meeting to explain operating results of the current quarter to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

February 9, 2021

URL: <http://www.fujifilmholdings.com/en>

1. Results of Nine months ended December 31, 2020 (From April 1, 2020 to December 31, 2020)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
		%		%		%		%
Nine months ended Dec. 31, 2020	1,573,434	(9.0)	120,468	(20.6)	174,821	5.0	126,489	4.8
Nine months ended Dec. 31, 2019	1,728,397	(4.0)	151,635	(4.2)	166,530	7.7	120,658	19.4

Note: Comprehensive income

3rd Quarter ended December 31, 2020 ¥ 149,876 million (24.5 %) 3rd Quarter ended December 31, 2019 ¥ 120,352 million (0.1 %)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)
	Yen	Yen
Nine months ended Dec. 31, 2020	316.42	315.36
Nine months ended Dec. 31, 2019	294.76	293.84

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets
				%
As of Dec. 31, 2020	3,369,919	2,124,198	2,081,004	61.8
As of March 31, 2020	3,321,692	1,993,757	1,953,252	58.8

2. Cash Dividends

	Cash dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2020	-	47.50	-	47.50	95.00
Year ending March 31, 2021	-	47.50	-		
Year ending March 31, 2021 (Forecast)				52.50	100.00

Note: Changes in dividends forecast during the quarter under review: Yes

3. Forecast for the Fiscal Year ending March 31, 2021 (From April 1, 2020 to March 31, 2021)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%: Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share
		%		%		%		%	Yen
For the Year ending March 31, 2021	2,180,000	(5.8)	160,000	(14.2)	210,000	21.3	160,000	28.0	400.22

Note: Changes in forecast which was recently announced: Yes

Note: Net income attributable to FUJIFILM Holdings per share is calculated using the number of shares issued as of December 31, 2020 excluding treasury shares for the average number of shares for the relevant period.

Notes

(1) Changes in status of material subsidiaries during this quarter

(Company newly consolidated or removed from consolidation): None

(2) Adoption of simplified method of accounting or specific accounting treatments: None

(3) Changes in accounting principles

1. Changes in accounting policies accompanied by revisions of accounting standards: None

2. Changes in accounting policies other than 1. above: None

(4) Number of shares outstanding

1. Issued (including treasury stock):

2. Treasury stock:

3. Average number of shares:

As of Dec. 31, 2020	514,625,728	As of March 31, 2020	514,625,728
As of Dec. 31, 2020	114,844,556	As of March 31, 2020	114,914,288
Nine months ended Dec. 31, 2020	399,752,967	Nine months ended Dec. 31, 2019	409,348,775

This report is not reviewed.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have an intention of guaranteeing the realization of the forecasts. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecasts and warnings for users of the forecasts are mentioned in the page 7, (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results in 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER.

[INDEX]

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER		
(1) Explanation on Consolidated Operating Results	• • • • •	P. 2
(2) Explanation on the Consolidated Financial Position	• • • • •	P. 6
(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results	• • • • •	P. 7
2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION		
(1) Changes in Status of Material Subsidiaries during This Quarter (Company Newly Consolidated or Removed from Consolidation)	• • • • •	P. 7
(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments	• • • • •	P. 7
(3) Changes in Accounting Principles	• • • • •	P. 7
3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION	• • • • •	P. 7
4. CONSOLIDATED FINANCIAL STATEMENTS		
(1) Consolidated Balance Sheets	• • • • •	P. 8
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	• • • • •	P. 10
(Consolidated Statements of Income)	• • • • •	P. 10
Nine months ended December 31	• • • • •	P. 10
Three months ended December 31	• • • • •	P. 11
(Consolidated Statements of Comprehensive Income)	• • • • •	P. 12
Nine months ended December 31	• • • • •	P. 12
Three months ended December 31	• • • • •	P. 12
(3) Consolidated Statements of Cash Flows	• • • • •	P. 13
(4) Notes to Consolidated Financial Statements	• • • • •	P. 14
Note Relating to the Going Concern Assumption	• • • • •	P. 14
Segment Information	• • • • •	P. 14
1. Nine months ended December 31	• • • • •	P. 14
2. Three months ended December 31	• • • • •	P. 16
Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity	• • • • •	P. 16

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER

(1) Explanation on Consolidated Operating Results

Amount Unit: Billions of yen

	Nine months ended December 31, 2020		Nine months ended December 31, 2019		Change	
					Amount	%
Domestic revenue	41.7%	656.7	42.3%	730.5	(73.8)	(10.1)
Overseas revenue	58.3%	916.7	57.7%	997.9	(81.2)	(8.1)
Revenue	100.0%	1,573.4	100.0%	1,728.4	(155.0)	(9.0)
Operating income	7.7%	120.5	8.8%	151.6	(31.1)	(20.6)
Income before income taxes	11.1%	174.8	9.6%	166.5	8.3	5.0
Net income attributable to FUJIFILM Holdings	8.0%	126.5	7.0%	120.7	5.8	4.8
Exchange rates (Yen / US\$)		¥106		¥109		(¥3)
Exchange rates (Yen / Euro)		¥123		¥121		¥2

In the nine months ended December 31, 2020, the Fujifilm Group recorded ¥1,573.4 billion in consolidated revenue (down 9.0% year-over-year), reflecting such factors as sales increases in the bio CDMO business and electronic materials business, and sales decreases in the document business, photo imaging business, and graphic systems business.

Operating income increased to ¥120.5 billion (down 20.6% year-over-year). Consolidated income before income taxes amounted to ¥174.8 billion (up 5.0% year-over-year) and consolidated net income attributable to FUJIFILM Holdings totaled ¥126.5 billion (up 4.8% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during the nine months ended December 31, 2020 were ¥106 and ¥123, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Nine months ended December 31, 2020	Nine months ended December 31, 2019	Change	
			Amount	%
Imaging Solutions	218.6	266.1	(47.5)	(17.9)
Healthcare & Material Solutions	737.0	741.2	(4.2)	(0.6)
Document Solutions	617.8	721.1	(103.3)	(14.3)
Consolidated Total	1,573.4	1,728.4	(155.0)	(9.0)

Operating Income by Operating Segment

Amount Unit: Billions of yen

Segment	Nine months ended December 31, 2020	Nine months ended December 31, 2019	Change	
			Amount	%
Imaging Solutions	14.1	27.4	(13.3)	(48.5)
Healthcare & Material Solutions	82.6	70.8	11.8	16.7
Document Solutions	46.2	80.5	(34.3)	(42.6)
Corporate Expenses and Eliminations	(22.4)	(27.1)	4.7	-
Consolidated Total	120.5	151.6	(31.1)	(20.6)

Imaging Solutions

In the Imaging Solutions segment, consolidated revenue amounted to ¥218.6 billion (down 17.9% year-over-year).

Consolidated operating income amounted to ¥14.1 billion (down 48.5% year-over-year).

In the photo imaging business, revenue decreased due to the impact of voluntary restraint and cancellation of events resulting from the spread of the COVID-19 pandemic, but sales of instant photo systems, which enable users to enjoy on-the-spot printing of photos, increased in the third quarter compared year-over-year. For instant photo systems, we are expanding online sales by using social media to promote a new way of enjoying *instax* at home. As a result, sales recovered, particularly in Europe and China. Sales were strong for the *instax mini Link* smartphone printer, and in May 2020 we provided customers with added value and a new way to enjoy the printer by adding the new “Sketch, edit & print” feature to the printer’s dedicated app. The new feature enables users to export sketches and text from photos taken on their smartphones to merge them with other photos and print them. Sales of the *instax mini II* instant camera, launched in March 2020, also achieved a solid increase in sales, and in November 2020, we launched the *instax SQUARE SQ1*, an entry model compatible with the popular square format film. Also, in April 2020, new personalized features were added to the *Year Album*, a photo book service, enabling automatic selection and layout of photos according to individual interests and preferences through the use of AI technology. The new features have been well received by users. We will continue communicating to the world the traditional photographic values of “shooting, preserving, displaying, and gifting,” as well as delivering innovative, user-friendly products and services, thereby meeting increasingly diversified customer needs.

In the optical device and electronic imaging business, revenue from the electronic imaging field, which plunged in the first half due to reduced demand resulting from the COVID-19 pandemic, recovered year-over-year in the third quarter. Regarding mirrorless digital cameras, sales of the *FUJIFILM X-T4*, launched in April 2020, increased steadily, and sales of the *FUJIFILM X-S10*, launched in November 2020 with highly regarded features including compact size, easy-to-hold grip and powerful image stabilization, were strong mainly in Japan and China. In July 2020, we launched the *FUJINON Lens GF30mmF3.5 R WR* as a new interchangeable lens for the *GFX* Series, providing a compact wide-angle prime lens that delivers ultra-high resolution. As interchangeable lenses for the *X* Series, we launched the *FUJINON Lens XF50mmF1.0 R WR*, a large-diameter mid-telephoto prime lens, in September 2020, and the *FUJINON Lens XF10-24mmF4 R OIS WR*, a ultra-wide angle zoom lens, in November 2020, thereby enhancing the appeal of our products as systems through an extensive lineup of lenses. Going forward, we will continue providing value-added products and revitalizing the market, along with providing the pleasure of taking photos.

In the optical device field, sales of monitoring zoom lens and integrated surveillance camera were favorable, but revenue of broadcast and cinema lenses decreased due to the cancellation of sports and events as well as suspended filming of television dramas and movies. Aiming to achieve business growth in this field, we are expanding our business domains and developing innovative products that satisfy the diverse needs of the market, including the development and launch of ultra-short-throw projectors and long-throw security cameras, and the new development of multispectral camera systems.

Healthcare & Material Solutions

In the Healthcare & Material Solutions segment, consolidated revenue amounted to ¥737.0 billion (down 0.6% year-over-year).

Consolidated operating income amounted to ¥82.6 billion (up 16.7% year-over-year).

In the medical systems business, revenue declined overall due to the COVID-19 pandemic. However, revenue increased significantly in the antibacterial materials field, which witnessed a surge in sales of products such as medicated hand gel and antibacterial wipes that make use of our proprietary *Hydro Ag+* technology combining the disinfectant effect of alcohol with the sustained disinfection of a silver-based

antibacterial agent and a hyper-hydrophilic coating. In the X-ray imaging diagnostics field, robust demand continued for the *FUJIFILM DR CALNEO AQRO* and *FUJIFILM DR CALNEO Go PLUS*, which are mobile digital X-ray imaging systems that can be moved freely between hospital bedsides for screening. Sales of these products remained strong in the United States, Europe, and Asia. In the ultrasound diagnostics field, revenue increased due to solid sales of the *Sonosite PX*, a high-end ultrasound diagnostic device, launched in the U.S. in July 2020 and in Europe in August 2020, and reflecting an increase in demand in Japan and other countries amid the COVID-19 pandemic. The medical IT field witnessed strong sales of systems, particularly the *SYNAPSE*, Picture Archiving and Communication Systems (PACS), mainly in Japan and China. In December 2020, we released an upgraded version of *NEXUS*, an endoscope information management system, which features a new function designed by using AI technology that supports endoscopy report preparation. In the endoscopes field, robust sales were seen in China for such products as the *7000* system, capable of special-light observation. In November 2020, we launched *CAD EYE™*, an endoscopic diagnosis support function, in Japan, which enables real-time detection and characterization of colon polyps and other lesions using AI technology. In the In Vitro Diagnostics (IVD) field, despite the impact of COVID-19, sales of the *DRI-CHEM* series of blood examination systems were solid because of the increased demand for veterinary diagnostics in the overseas market.

In the pharmaceutical business, revenue increased due to such factors as licensing revenue under the Tripartite Licensing Agreement signed in June 2020 with Dr. Reddy's Laboratories Ltd., a major pharmaceutical company headquartered in India, and Global Response Aid, a global provider of medical supplies and pharmaceuticals. This agreement targeted deployment outside Japan of the anti-influenza virus drug *Avigan® Tablet* (generic name: *favipiravir*), which shows promise as a COVID-19 treatment. Regarding *Avigan® Tablet* targeting COVID-19 patients, the phase III clinical trial was conducted in Japan and production capacity increased. The Fujifilm Group will continue contributing to the further development of medicine by supplying high-value-added pharmaceutical products.

In the bio CDMO business, revenue increased as biopharmaceutical process development and manufacturing under contract progressed favorably. In January 2021, we announced an investment of more than ¥200 billion to establish a new large-scale biopharmaceutical production site in the U.S. to accelerate the growth of the bio CDMO business. In addition to contracting mass production of drug substances, the facility will also provide end-to-end services from drug substance production, to formulation and packing. The new site is scheduled to begin operations in the spring of 2025. In the gene therapy field, the market for which is expected to expand, we will invest approximately ¥4 billion to establish a contract process development / substance production site for gene therapy drugs. This site is scheduled to begin operations in the fall of 2021. We are committed to contributing to the solution of social issues and the development of the healthcare industry by such means as addressing unmet medical needs through the stable supply of high-quality pharmaceuticals.

In the regenerative medicine business, sales of cell culture media for biopharmaceuticals by FUJIFILM Irvine Scientific Inc. (based in the U.S.) were strong reflecting a rise in demand in line with rapid mass production of vaccines and antibody drugs for COVID-19 treatment. The contract development business operated by FUJIFILM Cellular Dynamics, Inc. (also based in the U.S.) for allogeneic iPS cells used in next-generation cancer immunotherapeutic drugs also fared well. In November 2020, FCDI started full-scale supplying of iPS cells for treatment and patent licensing related to iPS cell generation technology. The first agreement was signed with Lonza Walkersville, Inc. to grant the non-exclusive right to use the patent related to iPS cell generation technology worldwide for the development of regenerative medicine products. We will continue contributing to a fast containment of the COVID-19 pandemic and early commercialization of regenerative medicine by leveraging the technologies and expertise of our group companies.

In the life sciences business, although sales at stores were affected by the COVID-19 pandemic, total revenue increased as sales of supplements such as *MetabARRIER EX* were strong, particularly via online channels. In April 2020 we launched *Astalift Supplement White Shield* and *Astalift Drink White Shield*, which

are Foods with Functional Claims (a category of health food products in Japan) that help to protect the skin from harmful UV rays. These were followed in September 2020 with the launch of *Astalift Luminous Essence*, a foundation makeup incorporating an ingredient that retains water to preserve the skin's moisture, and *Astalift Sparkle Tight Serum*, which uses bursting bubbles to tighten the skin. We will continue to provide unique products that meet customer needs and contribute to people's beauty and health promotion.

In the display materials business, overall revenue increased due to the rise in demand for monitors and tablets, and the steady sales of televisions amid the COVID-19 pandemic.

In the industrial products business, sales of the *EXCLEAR* touch-panel sensor films showed steady growth due to increased demand for mobile PCs for work-from-home and school-from-home, although sales of products such as equipment and materials for non-destructive inspection decreased due to the COVID-19 pandemic.

In the electronic materials business, revenue increased due to buoyant sales of materials for data center servers, reflecting more widespread work-from-home amid the COVID-19 pandemic, as well as Chemical Mechanical Planarization (CMP) slurries and advanced resists used for smartphones and other advanced logic devices, demand for which is recovering. In response to growing semiconductor demand, we will further expand the business with a focus on materials for advanced processes, thereby contributing to the creation of social value in the 5G/IoT era.

In the fine chemical business, despite the impact of factors such as reduced demand for reagents caused by delays in research activities at universities and corporations resulting from the spread of COVID-19, overall revenue increased due to solid sales of disinfection ethanol and other products reflecting higher demand.

In the recording media business, corporate activities stagnated under the COVID-19 pandemic, while corporations prioritized the enhancement of network infrastructure to support work-from-home demand over investment in data archiving. This resulted in lower revenue due to reduced demand for magnetic data storage tape. Over the medium- to long-term, however, we believe that data volume will continue to increase and magnetic data storage tape will retain its superiority. We aim to expand the business by extending our lineup of products and services that cater to the needs of our customers in the big data era.

In the graphic systems business, revenue decreased due to reduced demand for printing plates under the impact of the COVID-19 pandemic. Henceforth, we intend to promote sales of process-less CTP plates and other environmentally friendly products. In the digital printing field, we will continue to aim for business growth by developing and providing innovative products such as the *Jet Press750S*, a commercial inkjet digital press, to the commercial and package printing market, where digitization is advancing.

In the inkjet business, overall revenue fell as the demand for ink in the wide format printer market in Europe decreased sharply, although sales of industrial inkjet printheads benefitted from a recovery trend in the Chinese ceramic market. We will continue to develop and supply innovative products for the industrial inkjet printer market, whose areas of application are expanding, thereby contributing to the advancement of various industries.

Document Solutions

In the Document Solutions segment, consolidated revenue amounted to ¥617.8 billion (down 14.3% year-over-year).

Consolidated operating income amounted to ¥46.2 billion (down 42.6% year-over-year).

In the office products field in the office products and printers business, the number of unit sales increased year-over-year in Japan, China, and the Asia-Pacific region. In the office printers field, sales volume decreased year-over-year.

In the production services business, sales volume decreased year-over-year as customers curtailed investment due to economic uncertainties resulting from the COVID-19 pandemic.

In the solutions and services business, sales activities were restricted due to the impact of the COVID-19 pandemic, resulting in a decrease in overall revenue.

Sales of solutions for supporting work-from-home and other new work styles, which are becoming the norm due to the COVID-19 pandemic, are growing steadily. In Japan, demand increased for *Netprint® Service*, that allows user to use multi-copiers installed at Seven-Eleven stores nationwide to print files that have been registered via the internet. Also, domestic and overseas sales of document handling software *DocuWorks®*, which enables electronic document management as if handling paper documents, have reached a cumulative total of 7.7 million licenses. We will continue introducing new solutions and services, including *beat*, a service that provides strong security and an easy and convenient network environment, as well as paperless fax solutions for home-based access to faxes sent to offices, and digital signature service, with the aim of supporting customers' diversifying work styles and achieve further growth in this business domain.

(2) Explanation on the Consolidated Financial Position

At the end of the third quarter of the fiscal year ending March 31, 2021, total assets increased by ¥48.2 billion, compared with the end of the previous fiscal year, to ¥3,369.9 billion, owing to an increase in cash and cash equivalents. Total liabilities decreased by ¥82.2 billion compared with the end of the previous fiscal year, to ¥1,245.7 billion. FUJIFILM Holdings shareholders' equity increased by ¥127.7 billion, compared with the end of the previous fiscal year, to ¥2,081.0 billion. As a result, the current ratio increased by 18.6 percentage points, to 244.2%, the debt-equity ratio decreased by 8.1 percentage points, to 59.9%, and the equity ratio increased by 3.0 percentage points, to 61.8%, compared with the end of the previous fiscal year. The Fujifilm Group is maintaining a stable level of asset liquidity and a sound capital structure.

(Cash Flows)

Amount Unit: Billions of yen

	Nine months ended December 31, 2020	Nine months ended December 31, 2019	Change
Net cash provided by operating activities	292.4	162.4	130.0
Net cash used in investing activities	(79.9)	(202.4)	122.5
Net cash used in financing activities	(117.7)	(150.0)	32.3

During the nine months ended December 31, 2020, net cash provided by operating activities totaled ¥292.4 billion, due to a decrease in accounts receivable and other factors. Net cash used in investing activities amounted to ¥79.9 billion, due to the acquisition of property, plant, equipment, and other factors. Thus, free cash flow—or the sum of cash flow from operating and investing activities— was ¥212.5 billion. Net cash used in financing activities amounted to ¥117.7 billion, due to a decrease in debts and other factors.

As a result, cash and cash equivalents at the end of the quarter under review amounted to ¥494.8 billion, up ¥98.7 billion year-over-year.

(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results

Amount Unit: Billions of yen

	Previous forecast (A) (announced on November 10, 2020)	Latest revised forecast (B)	Change (B-A)	Change (%)	(Ref.) Actual results for year ending March 31, 2020
Revenue	2,210.0	2,180.0	(30.0)	(1.4%)	2,315.1
Operating income	143.0	160.0	17.0	11.9%	186.6
Income before income taxes	175.0	210.0	35.0	20.0%	173.1
Net income attributable to FUJIFILM Holdings	125.0	160.0	35.0	28.0%	125.0
Net income attributable to FUJIFILM Holdings per share	¥312.68	¥400.22	¥87.54	28.0%	¥306.18
ROE (%)	6.3%	7.8%	-	1.5% points	6.3%
Exchange rates (Yen / US\$)	¥108	¥106	(¥2)	-	¥109
Exchange rates (Yen / Euro)	¥120	¥123	¥3	-	¥121

Note: Net income attributable to FUJIFILM Holdings per share in the previous forecast is calculated using the number of shares issued as of September 30, 2020 excluding treasury shares for the average number of shares for the relevant period, that in the latest revised forecast is calculated using the number of shares issued as of December 31, 2020, excluding treasury shares.

In the forecast for the fiscal year ending March 31, 2021, revenue has been revised downward due to the rebound of COVID-19 pandemic which has affected certain business. However, we have revised operating income upward reflecting strong performance of such business as healthcare and highly functional materials field. In the operating income forecast, we have included Healthcare & Materials Solution factors such as the impact of the transfer of shares of a subsidiary as we disclosed “Notice of Execution of Tender Offer Application Agreement Pertaining to Tender Offer for Shares of Subsidiary” on January 29, 2021, as well as impacts on optimizing the business portfolio in other healthcare field. In addition, income before income taxes and net income attributable to FUJIFILM Holdings will also be revised upward reflecting such factors as gains on investment securities. One-time cost of ¥25.0 billion is expected such as for the brand renewal for the Document Solutions segment. The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year ending March 31, 2021, are ¥106 and ¥123, respectively.

2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION

(1) Changes in Status of Material Subsidiaries during This Quarter (Company Newly Consolidated or Removed from Consolidation): None

(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments: None

(3) Changes in Accounting Principles: None

3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION: NONE

Note: This document is a faithful translation into English of an earnings report prepared in Japanese by FUJIFILM Holdings Corporation in accordance with Tokyo Stock Exchange guidelines.

Accordingly, the explanations for each business segment may include references to products that are marketed under different product names overseas or are not marketed overseas and may also include references to product marketing periods that differ by region.

“Xerox” is a registered trademark of Xerox Corporation in the United States and other countries. All other product names contained in this material are trademarks of their respective companies.

4. CONSOLIDATED FINANCIAL STATEMENTS

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of December 31, 2020	As of March 31, 2020	Change
ASSETS			
Current assets:			
Cash and cash equivalents	494,767	396,091	98,676
Notes and accounts receivable:			
Trade	497,443	524,120	(26,677)
Lease receivable	52,732	55,419	(2,687)
Affiliated companies	3,479	2,640	839
Allowance for doubtful receivables	(23,652)	(23,761)	109
	530,002	558,418	(28,416)
Inventories	406,894	380,911	25,983
Prepaid expenses and Other	92,527	153,783	(61,256)
Total current assets	1,524,190	1,489,203	34,987
Investments and long-term receivables:			
Investments in and advances to affiliated companies	27,542	27,770	(228)
Investment securities	105,259	87,209	18,050
Long-term lease receivables	59,673	61,724	(2,051)
Other long-term receivables	24,032	30,497	(6,465)
Allowance for doubtful receivables	(3,473)	(4,067)	594
Total investments and long-term receivables	213,033	203,133	9,900
Property, plant and equipment:			
Land	98,752	96,776	1,976
Buildings	749,755	732,716	17,039
Machinery and equipment and other	1,495,194	1,478,270	16,924
Construction in progress	54,154	47,481	6,673
	2,397,855	2,355,243	42,612
Less accumulated depreciation	(1,782,671)	(1,754,696)	(27,975)
Total property, plant and equipment	615,184	600,547	14,637
Other assets:			
Operating lease right-of-use assets	76,145	75,261	884
Goodwill, net	685,880	687,155	(1,275)
Other intangible assets, net	135,608	142,071	(6,463)
Other	119,879	124,322	(4,443)
Total other assets	1,017,512	1,028,809	(11,297)
Total assets	3,369,919	3,321,692	48,227

Amount Unit: Millions of yen

	As of December 31, 2020	As of March 31, 2020	Change
LIABILITIES			
Current liabilities:			
Short-term debt	79,248	120,998	(41,750)
Notes and accounts payable:			
Trade	188,594	195,214	(6,620)
Construction	13,870	25,360	(11,490)
Affiliated companies	1,959	1,724	235
	204,423	222,298	(17,875)
Accrued income taxes	20,682	24,893	(4,211)
Accrued liabilities	160,308	171,989	(11,681)
Short-term operating lease liabilities	26,489	25,696	793
Other current liabilities	133,045	94,133	38,912
Total current liabilities	624,195	660,007	(35,812)
Long-term liabilities:			
Long-term debt	466,113	503,171	(37,058)
Accrued pension and severance costs	26,637	33,818	(7,181)
Long-term operating lease liabilities	52,581	52,652	(71)
Other long-term liabilities	76,195	78,287	(2,092)
Total long-term liabilities	621,526	667,928	(46,402)
Total liabilities	1,245,721	1,327,935	(82,214)
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 800,000,000 shares			
Issued: 514,625,728 shares			
Retained earnings	2,668,885	2,563,091	105,794
Accumulated other comprehensive income (loss)	(142,435)	(164,100)	21,665
Treasury stock, at cost	(485,809)	(486,102)	293
Total FUJIFILM Holdings shareholders' equity	2,081,004	1,953,252	127,752
Noncontrolling interests	43,194	40,505	2,689
Total equity	2,124,198	1,993,757	130,441
Total liabilities and equity	3,369,919	3,321,692	48,227

Note: Details of accumulated other comprehensive income (loss)

	As of December 31, 2020	As of March 31, 2020	Change
Unrealized gains (losses) on securities	(28)	(11)	(17)
Foreign currency translation adjustments	(30,957)	(46,201)	15,244
Pension liability adjustments	(111,512)	(117,780)	6,268
Unrealized gains (losses) on derivatives	62	(108)	170

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

Nine months ended December 31

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020		Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019		Change	
					Amount	%
	%		%			
Revenue	100.0	1,573,434	100.0	1,728,397	(154,963)	(9.0)
Cost of sales	58.6	922,495	58.2	1,005,332	(82,837)	(8.2)
Gross profit	41.4	650,939	41.8	723,065	(72,126)	(10.0)
Operating expenses:						
Selling, general and administrative	26.7	419,722	26.2	453,434	(33,712)	(7.4)
Research and development	7.0	110,749	6.8	117,996	(7,247)	(6.1)
	33.7	530,471	33.0	571,430	(40,959)	(7.2)
Operating income	7.7	120,468	8.8	151,635	(31,167)	(20.6)
Other income (expenses):						
Interest and dividend income		3,346		4,217	(871)	
Interest expense		(2,010)		(1,931)	(79)	
Foreign exchange gains (losses), net		(5,659)		(1,580)	(4,079)	
Gains (losses) on equity securities, net		39,770		1,990	37,780	
Other, net		18,906		12,199	6,707	
	3.4	54,353	0.8	14,895	39,458	264.9
Income before income taxes	11.1	174,821	9.6	166,530	8,291	5.0
Income taxes	2.9	46,195	1.9	33,041	13,154	39.8
Equity in net earnings (losses) of affiliated companies	(0.1)	(841)	(0.0)	(38)	(803)	2,113.2
Net income	8.1	127,785	7.7	133,451	(5,666)	(4.2)
Less: Net (income) loss attributable to the noncontrolling interests	(0.1)	(1,296)	(0.7)	(12,793)	11,497	(89.9)
Net income attributable to FUJIFILM Holdings	8.0	126,489	7.0	120,658	5,831	4.8

Three months ended December 31

Amount Unit: Millions of yen

	Three months ended December 31, 2020 From October 1, 2020 To December 31, 2020		Three months ended December 31, 2019 From October 1, 2019 To December 31, 2019		Change	
					Amount	%
	%		%			
Revenue	100.0	576,045	100.0	596,263	(20,218)	(3.4)
Cost of sales	56.0	322,342	58.2	346,782	(24,440)	(7.0)
Gross profit	44.0	253,703	41.8	249,481	4,222	1.7
Operating expenses:						
Selling, general and administrative	26.6	153,366	25.4	151,573	1,793	1.2
Research and development	6.3	36,340	6.4	38,312	(1,972)	(5.1)
	32.9	189,706	31.8	189,885	(179)	(0.1)
Operating income	11.1	63,997	10.0	59,596	4,401	7.4
Other income (expenses):						
Interest and dividend income		1,443		1,545	(102)	
Interest expense		(905)		(555)	(350)	
Foreign exchange gains (losses), net		(1,947)		1,156	(3,103)	
Gains (losses) on equity securities, net		8,545		2,667	5,878	
Other, net		4,119		4,589	(470)	
	2.0	11,255	1.6	9,402	1,853	19.7
Income before income taxes	13.1	75,252	11.6	68,998	6,254	9.1
Income taxes	3.1	17,593	1.4	8,093	9,500	117.4
Equity in net earnings (losses) of affiliated companies	0.3	1,810	0.1	537	1,273	237.1
Net income	10.3	59,469	10.3	61,442	(1,973)	(3.2)
Less: Net (income) loss attributable to the noncontrolling interests	(0.1)	(586)	(0.3)	(1,929)	1,343	(69.6)
Net income attributable to FUJIFILM Holdings	10.2	58,883	10.0	59,513	(630)	(1.1)

(Consolidated Statements of Comprehensive Income)**Nine months ended December 31**

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020	Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019	Change
Net income	127,785	133,451	(5,666)
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	(17)	(7)	(10)
Foreign currency translation adjustments	15,477	(16,809)	32,286
Pension liability adjustments	6,461	3,425	3,036
Unrealized gains (losses) on derivatives	170	292	(122)
Total	22,091	(13,099)	35,190
Comprehensive income (loss)	149,876	120,352	29,524
Less: Comprehensive (income) loss attributable to noncontrolling interests	(1,722)	(8,830)	7,108
Comprehensive income (loss) attributable to FUJIFILM Holdings	148,154	111,522	36,632

Three months ended December 31

Amount Unit: Millions of yen

	Three months ended December 31, 2020 From October 1, 2020 To December 31, 2020	Three months ended December 31, 2019 From October 1, 2019 To December 31, 2019	Change
Net income	59,469	61,442	(1,973)
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	(8)	4	(12)
Foreign currency translation adjustments	6,235	33,797	(27,562)
Pension liability adjustments	1,207	1,040	167
Unrealized gains (losses) on derivatives	35	157	(122)
Total	7,469	34,998	(27,529)
Comprehensive income (loss)	66,938	96,440	(29,502)
Less: Comprehensive (income) loss attributable to noncontrolling interests	(700)	(2,563)	1,863
Comprehensive income (loss) attributable to FUJIFILM Holdings	66,238	93,877	(27,639)

(3) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020	Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019	Change
Operating activities			
Net income	127,785	133,451	(5,666)
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	90,884	91,812	(928)
(Gains) losses on equity securities, net	(39,770)	(1,990)	(37,780)
Equity in net (gains) losses of affiliated companies, net of dividends received	1,112	1,360	(248)
Changes in operating assets and liabilities:			
Notes and accounts receivable	37,225	43,462	(6,237)
Inventories	(29,901)	(38,151)	8,250
Notes and accounts payable - trade	(10,436)	6,521	(16,957)
Accrued income taxes and other liabilities	(3,138)	(18,363)	15,225
Other	118,648	(55,704)	174,352
Subtotal	164,624	28,947	135,677
Net cash provided by operating activities	292,409	162,398	130,011
Investing activities			
Purchases of property, plant and equipment	(72,894)	(64,763)	(8,131)
Purchases of software	(15,400)	(15,152)	(248)
Proceeds from sales and maturities of marketable and investment securities	23,339	104	23,235
Purchases of marketable and investment securities	(1,338)	(1,850)	512
(Increase) decrease in time deposits, net	(772)	(2,039)	1,267
Increase in investments in and advances to affiliated companies	(2,673)	(1,001)	(1,672)
Acquisitions of businesses, net of cash acquired	-	(105,904)	105,904
Other	(10,184)	(11,797)	1,613
Net cash used in investing activities	(79,922)	(202,402)	122,480
Financing activities			
Proceeds from long-term debt	2,473	50,096	(47,623)
Repayments of long-term debt	(31,330)	(62,040)	30,710
Increase (decrease) in short-term debt with maturities of three months or less, net	(934)	(1,254)	320
Proceeds from short-term debt with maturities longer than three months	-	150,000	(150,000)
Payments of short-term debt with maturities longer than three months	(50,000)	-	(50,000)
Cash dividends paid to shareholders	(37,975)	(35,817)	(2,158)
Subsidiaries' cash dividends paid to noncontrolling interests	(1,306)	(9,796)	8,490
Net purchases of stock for treasury	(12)	(15)	3
Capital transactions with noncontrolling interests and other	1,429	(241,125)	242,554
Net cash used in financing activities	(117,655)	(149,951)	32,296
Effect of exchange rate changes on cash and cash equivalents	3,844	(7,269)	11,113
Net increase (decrease) in cash and cash equivalents	98,676	(197,224)	295,900
Cash and cash equivalents at beginning of period	396,091	654,747	(258,656)
Cash and cash equivalents at end of period	494,767	457,523	37,244

(4) Notes to Consolidated Financial Statements

Note Relating to the Going Concern Assumption

N/A

Segment Information

1. Nine months ended December 31

(A) Operating Segment Information

a. Revenue

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020		Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019		Change	
					Amount	%
Revenue:	%		%			
Imaging Solutions:						
External customers	13.9	218,646	15.4	266,164	(47,518)	(17.9)
Intersegment		1,401		1,738	(337)	—
Total		220,047		267,902	(47,855)	(17.9)
Healthcare & Material Solutions:						
External customers	46.8	736,954	42.9	741,170	(4,216)	(0.6)
Intersegment		1,037		1,345	(308)	—
Total		737,991		742,515	(4,524)	(0.6)
Document Solutions:						
External customers	39.3	617,834	41.7	721,063	(103,229)	(14.3)
Intersegment		4,620		9,777	(5,157)	—
Total		622,454		730,840	(108,386)	(14.8)
Eliminations		(7,058)		(12,860)	5,802	—
Consolidated total	100.0	1,573,434	100.0	1,728,397	(154,963)	(9.0)

b. Operating income

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020		Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019		Change	
					Amount	%
Operating Income:	%		%			
Imaging Solutions	6.4	14,130	10.2	27,431	(13,301)	(48.5)
Healthcare & Material Solutions	11.2	82,630	9.5	70,818	11,812	16.7
Document Solutions	7.4	46,211	11.0	80,469	(34,258)	(42.6)
Total		142,971		178,718	(35,747)	(20.0)
Corporate expenses and eliminations		(22,503)		(27,083)	4,580	—
Consolidated total	7.7	120,468	8.8	151,635	(31,167)	(20.6)

Note: The major products and services of each operating segment are as follows:

Imaging Solutions:	Color films, digital cameras, color paper, services and equipment for photofinishing, instant photo systems and optical devices
Healthcare & Material Solutions:	Equipment and materials for medical systems, cosmetics and supplements, pharmaceuticals, contract development and manufacturing organization of biopharmaceuticals, regenerative medicine, fine chemicals, equipment and materials for graphic arts, inks and industrial inkjet printheads, display materials, recording media, electronic materials
Document Solutions:	Digital MFPs, publishing systems, document management software and related solutions and services

(B) Geographic Information**a. Revenue**

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020		Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019		Change	
					Amount	%
Revenue:	%		%			
Japan:						
External customers	46.8	735,149	48.7	842,415	(107,266)	(12.7)
Intersegment		338,605		337,052	1,553	-
Total		1,073,754		1,179,467	(105,713)	(9.0)
The Americas:						
External customers	18.5	291,747	18.6	321,231	(29,484)	(9.2)
Intersegment		49,076		39,036	10,040	-
Total		340,823		360,267	(19,444)	(5.4)
Europe:						
External customers	11.8	185,552	10.4	179,989	5,563	3.1
Intersegment		8,570		12,316	(3,746)	-
Total		194,122		192,305	1,817	0.9
Asia and others:						
External customers	22.9	360,986	22.3	384,762	(23,776)	(6.2)
Intersegment		168,762		186,387	(17,625)	-
Total		529,748		571,149	(41,401)	(7.2)
Eliminations		(565,013)		(574,791)	9,778	-
Consolidated total	100.0	1,573,434	100.0	1,728,397	(154,963)	(9.0)

b. Operating income

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020		Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019		Change	
					Amount	%
Operating Income:	%		%			
Japan	5.0	53,701	7.3	86,366	(32,665)	(37.8)
The Americas	5.2	17,840	3.6	13,135	4,705	35.8
Europe	4.5	8,650	1.8	3,399	5,251	154.5
Asia and others	6.9	36,754	8.7	49,407	(12,653)	(25.6)
Eliminations		3,523		(672)	4,195	-
Consolidated total	7.7	120,468	8.8	151,635	(31,167)	(20.6)

c. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Nine months ended December 31, 2020 From April 1, 2020 To December 31, 2020		Nine months ended December 31, 2019 From April 1, 2019 To December 31, 2019		Change	
					Amount	%
Revenue:	%		%			
Domestic	41.7	656,728	42.3	730,461	(73,733)	(10.1)
Overseas:						
The Americas	18.9	298,028	18.6	322,901	(24,873)	(7.7)
Europe	12.3	192,270	13.1	225,921	(33,651)	(14.9)
Asia and others	27.1	426,408	26.0	449,114	(22,706)	(5.1)
Subtotal	58.3	916,706	57.7	997,936	(81,230)	(8.1)
Consolidated total	100.0	1,573,434	100.0	1,728,397	(154,963)	(9.0)

Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer's location.

2. Three months ended December 31**(A) Revenue by Operating Segment**

Amount Unit: Millions of yen

	Three months ended December 31, 2020 From October 1, 2020 To December 31, 2020		Three months ended December 31, 2019 From October 1, 2019 To December 31, 2019		Change	
					Amount	%
Revenue:	%		%			
Imaging Solutions	18.2	104,748	18.8	112,094	(7,346)	(6.6)
Healthcare & Material Solutions	45.8	263,633	41.7	248,425	15,208	6.1
Document Solutions	36.0	207,664	39.5	235,744	(28,080)	(11.9)
Consolidated total	100.0	576,045	100.0	596,263	(20,218)	(3.4)

Note: The major products and services of each operating segment are as follows:

Imaging Solutions	Color films, digital cameras, color paper, services and equipment for photofinishing, instant photo systems and optical devices
Healthcare & Material Solutions	Equipment and materials for medical systems, cosmetics and supplements, pharmaceuticals, contract development and manufacturing organization of biopharmaceuticals, regenerative medicine, fine chemicals, equipment and materials for graphic arts, inks and industrial inkjet printheads, display materials, recording media, electronic materials
Document Solutions	Digital MFPs, publishing systems, document management software and related solutions and services

(B) Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended December 31, 2020 From October 1, 2020 To December 31, 2020		Three months ended December 31, 2019 From October 1, 2019 To December 31, 2019		Change	
					Amount	%
Revenue:	%		%			
Domestic	40.0	230,630	40.0	238,532	(7,902)	(3.3)
Overseas:						
The Americas	19.4	112,000	20.0	119,064	(7,064)	(5.9)
Europe	13.6	78,164	14.4	86,070	(7,906)	(9.2)
Asia and others	27.0	155,251	25.6	152,597	2,654	1.7
Subtotal	60.0	345,415	60.0	357,731	(12,316)	(3.4)
Consolidated total	100.0	576,045	100.0	596,263	(20,218)	(3.4)

Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity

N/A